HomeCompareDKSHF vs PFE

DKSHF vs PFE: Dividend Comparison 2026

DKSHF yields 3.81% · PFE yields 6.20%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PFE wins by $4.2K in total portfolio value· pulled ahead in Year 10
10 years
DKSHF
DKSHF
● Live price
3.81%
Share price
$70.01
Annual div
$2.67
5Y div CAGR
23.5%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$46.8K
Annual income
$6,460.93
Full DKSHF calculator →
PFE
Pfizer Inc.
● Live price
6.20%
Share price
$27.76
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$51.1K
Annual income
$27,210.54
Full PFE calculator →

Portfolio growth — DKSHF vs PFE

📍 PFE pulled ahead of the other in Year 10

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodDKSHFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, DKSHF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
DKSHF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

DKSHF
Annual income on $10K today (after 15% tax)
$324.19/yr
After 10yr DRIP, annual income (after tax)
$5,491.79/yr
PFE
Annual income on $10K today (after 15% tax)
$526.66/yr
After 10yr DRIP, annual income (after tax)
$23,128.96/yr
At 15% tax rate, PFE beats the other by $17,637.17/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of DKSHF + PFE for your $10,000?

DKSHF: 50%PFE: 50%
100% PFE50/50100% DKSHF
Portfolio after 10yr
$49.0K
Annual income
$16,835.74/yr
Blended yield
34.39%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

DKSHF
Analyst Ratings
1
Hold
Consensus: Hold
Altman Z
5.8
Piotroski
7/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-0.9% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

DKSHF buys
0
PFE buys
0
No recent congressional trades found for DKSHF or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricDKSHFPFE
Forward yield3.81%6.20%
Annual dividend / share$2.67$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR23.5%13.2%
Portfolio after 10y$46.8K$51.1K
Annual income after 10y$6,460.93$27,210.54
Total dividends collected$22.9K$60.1K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldHold

Year-by-year: DKSHF vs PFE ($10,000, DRIP)

YearDKSHF PortfolioDKSHF Income/yrPFE PortfolioPFE Income/yrGap
1$11,171$471.02$9,161$701.38+$2.0KDKSHF
2$12,560$607.32$8,610$859.79+$4.0KDKSHF
3$14,228$788.15$8,366$1,081.25+$5.9KDKSHF
4$16,254$1,030.45$8,483$1,405.66+$7.8KDKSHF
5$18,751$1,358.75$9,084$1,907.24+$9.7KDKSHF
6$21,872$1,809.15$10,418$2,732.78+$11.5KDKSHF
7$25,839$2,435.77$13,007$4,193.56+$12.8KDKSHF
8$30,969$3,321.26$18,010$7,005.87+$13.0KDKSHF
9$37,731$4,594.49$28,216$12,979.89+$9.5KDKSHF
10← crossover$46,834$6,460.93$51,081$27,210.54$4.2KPFE

DKSHF vs PFE: Complete Analysis 2026

DKSHFStock

DKSH Holding AG provides various market expansion services in Thailand, Greater China, Malaysia, Singapore, rest of the Asia Pacific, and internationally. The company offers sourcing, marketing, sales, distribution, and after-sales services. It operates through four segments: Healthcare, Consumer Goods, Performance Materials, and Technology. The Healthcare segment provides various services, such as registration, regulatory, market entry studies, importation, customs clearance, marketing and sales, physical distribution, invoicing, and cash collection services for ethical pharmaceuticals, consumer health, and over-the-counter health products, as well as medical devices. The Consumer Goods segment offers a range of services, including product feasibility studies, registration, importation, customs clearance, marketing and merchandising, sales, warehousing, physical distribution, invoicing, cash collection, and after-sales services for fast moving consumer goods, food services, luxury goods, and fashion and lifestyle products, as well as hair and skin cosmetics. The Performance Materials segment sources, markets, and distributes a range of specialty chemicals and ingredients for the pharmaceutical, personal care, food and beverage, and industrial applications, as well as provides market expansion services for performance materials. The Technology segment offers market expansion services comprising a range of capital investment goods and analytical instruments in the areas of infrastructure, industrial materials and supplies, precision and textile machinery, semiconductors, photovoltaic and electronics, agriculture, and hospitality, as well as specialized industrial applications. The company was founded in 1865 and is based in Zurich, Switzerland.

Full DKSHF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this DKSHF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

DKSHF vs SCHDDKSHF vs JEPIDKSHF vs ODKSHF vs KODKSHF vs MAINDKSHF vs JNJDKSHF vs MRKDKSHF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.